Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)
Open accessAbstract
Introduction: Dysbetalipoproteinaemia (HLP3) is a disorder characterized by excess cholesterol-enriched, triglyceride-rich lipoprotein remnants in genetically predisposed individuals that powerfully promote premature cardiovascular disease if untreated.The current prevalence of HLP3 is largely unknown.Material and methods: We performed cross-sectional analysis of 128,485 U.S. adults from the Very Large Database of Lipids (VLDbL), using four algorithms to diagnose HLP3 employing three Vertical Auto Profile ultracentrifugation (UC) criteria and a previously described apolipoprotein B (apoB) method.We evaluated 4,926 participants from the 2011-2014 National Health and Nutrition Examination Survey (NHANES) with the apoB method.We examined demographic and lipid characteristics stratified by presence of HLP3 and evaluated lipid characteristics in those with HLP3 phenotype discordance and concordance as determined by apoB and originally defined UC criteria 1. Results: In U.S. adults in VLDbL and NHANES, a 1.7-2.0%prevalence is observed for HLP3 with the novel apoB method as compared to 0.2-0.8%prevalence in VLDbL via UC criteria 1-3.Participants who were both apoB and UC criteria HLP3 positive had higher remnant particles as well as more elevated triglyceride/apoB and total cholesterol/apoB ratios (all p < 0.001) than those who were apoB method positive and UC criteria 1 negative.Conclusions: HLP3 may be more prevalent than historically and clinically appreciated.The apoB method increases HLP3 identification via inclusion of milder phenotypes.Further work should evaluate the clinical implications of HLP3 diagnosis at various lipid algorithm cut-points to evaluate the ideal standard in the modern era.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Familial dysbetalipoproteinemia (FD) is a highly atherogenic, prevalent, genetically based lipid disorder.
“Familial dysbetalipoproteinemia (FD) is a highly atherogenic, prevalent genetically based lipid disorder.”
From Spectrum and Prevalence of Rare APOE Variants and Their Association with Familial Dysbetalipoproteinemia (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · see citing works
Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573 · see citing works
Flagged first, then by citations
Research works printed but not linked: 28
- [1]Fredrickson DS Levy RI Lees RS Fat transport in lipoproteins: an integrated approach to mechanisms and disorders N Engl J Med 1967 276 215 25 5333808
- [2]Mahley RW Huang Y Rall SC Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes J Lipid Res 1999 40 1933 49 10552997
- [3]Schaefer JR Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly Eur J Hum Genet 2009 17 541 2 19034315 PMC2986265
- [4]de Beer F Stalenhoef AFH Hoogerbrugge N Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia Arterioscler Thromb Vasc Biol 2002 22 294 9 11834531
- [5]Hopkins PN Brinton EA Nanjee MN Hyperlipoproteinemia type 3: the forgotten phenotype Curr Atheroscler Rep 2014 16 440 25079293
- [6]Sniderman AD Type III hyperlipoproteinemia: the forgotten, disregarded, neglected, overlooked, ignored but highly atherogenic, and highly treatable dyslipoproteinemia Clin Chem 2019 65 225 7 30538123
- [7]Soran H Adam S Mohammad JB Hypercholesterolaemia – practical information for non-specialists Arch Med Sci 2018 14 1 21 29379528 PMC5778427
- [8]Wood PD Stern MP Silvers A Reaven GM von der Groeben J Prevalence of plasma lipoprotein abnormalities in a free-living population of the Central Valley, California Circulation 1972 45 114 26 5007029
- [9]Jones GJL Hewitt D Godin GJ Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population Can Med Assoc J 1980 122 37 46 7363194 PMC1801586
- [10]Gibson TC Whorton EB The prevalence of hyperlipidemia in a natural community J Chronic Dis 1973 26 227 36 4351694
- [11]Sniderman AD Graaf J de Thanassoulis G Tremblay AJ Martin SS Couture P The spectrum of type III hyperlipoproteinemia J Clin Lipidol 2018 12 1383 9 30318453
- [12]Blom DJ O’Neill FH Marais AD Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations Clin Chem 2005 51 904 7 15855667
- [13]Sathiyakumar V Park J Quispe R Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-C and apolipoprotein B targets in selected worldwide dyslipidemia guidelines Circulation 2018 138 244 54 29506984
- [14]Sniderman A Couture P de Graaf J Diagnosis and treatment of apolipoprotein B dyslipoproteinemias Nat Rev Endocrinol 2010 6 335 46 20421882
- [15]Holewijn S Sniderman AD den Heijer M Swinkels DW Stalenhoef AFH de Graaf J Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study Eur J Clin Invest 2011 41 423 33 21128932
- [16]Martin SS Blaha MJ Toth PP Very large database of lipids: rationale and design Clin Cardiol 2013 36 641 8 24122913 PMC6649455
- [17]Rautela GS Liedtke RJ Automated enzymic measurement of total cholesterol in serum Clin Chem 1978 24 108 14 618640
- [18]Martin SS Blaha MJ Elshazly MB Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 2013 310 2061 8 24240933 PMC4226221
- [23]Sniderman A Tremblay A Bergeron J Gagné C Couture P Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B J Clin Lipidol 2007 1 256 63 21291689
- [25]Cromwell WC Otvos JD Keyes MJ LDL Particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management J Clin Lipidol 2007 1 583 92 19657464 PMC2720529
- [26]Salami JA Warraich H Valero-Elizondo J National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey JAMA Cardiol 2017 2 56 65 27842171
- [27]Marais AD Solomon GA Blom DJ Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E Crit Rev Clin Lab Sci 2014 51 46 62 24405372
- [28]Hoogwerf BJ Bantle JP Kuba K Frantz ID Hunninghake DB Treatment of type III hyperlipoproteinemia with four different treatment regimens Atherosclerosis 1984 51 251 9 6588975
- [29]Gaudet D Brisson D Tremblay K Targeting APOC3 in the familial chylomicronemia syndrome N Engl J Med 2014 371 2200 6 25470695
- [31]Farnier M Future lipid-altering therapeutic options targeting residual cardiovascular risk Curr Cardiol Rep 2016 18 65 27216845
- [32]Chung BH Wilkinson T Geer JC Segrest JP Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor J Lipid Res 1980 21 284 91 7381323
- [33]Kulkarni KR Cholesterol profile measurement by vertical auto profile method Clin Lab Med 2006 26 787 802 17110240
- [34]Boot CS Middling E Allen J Neely RDG Evaluation of the non-HDL cholesterol to apolipoprotein B ratio as a screening test for dysbetalipoproteinemia Clin Chem 2019 65 313 20 30538126
Cited by
Sorted by citations
Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria
Paquette, M., Trinder, M., Guay, S.-P., Brunham, L. R., & Baass, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae259 · Cited by 19 · see citing works
Blokhina, A. V., Ershova, A. I., Kiseleva, A. V., Sotnikova, E. A., Zharikova, A. A., Zaicenoka, M., Vyatkin, Y. V., Ramensky, V. E., Kutsenko, V. A., Garbuzova, E. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312651 · Cited by 8 · see citing works
- Authors
- Pallazola, V. A., Sathiyakumar, V., Park, J., Vakil, R. M., Toth, P., Lazo-Elizondo, M., Brown, E., Quispe, R., Guallar, E., Banach, M., Blumenthal, R. S., Jones, S., Marais, D., Soffer, D., Sniderman, A. D., & Martin, S.
- Affiliations
- Johns Hopkins University (US)
- University of Zielona Góra (PL)
- University of Cape Town (ZA)
- University of Pennsylvania Health System (US)
- McGill University Health Centre (CA)
- Corresponding author
- Martin, Seth
- ORCID
- Venue
- Archives of Medical Science
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2020
- Volume
- 16
- Issue
- 5
- Pages
- 993-1003
- ISSN
- 1734-1922 (ISSN-L)
- PMC
- PMC7444722
- OpenAlex
- W2969789686
- Cited by
- 38
- References
- 2
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 3
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Archives of Medical Science (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Aetna Foundation
- American Heart Association
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dysbetalipoproteinemia, type III hyperlipoproteinemia, prevalence, apolipoprotein B, remnant lipoproteins, triglyceride-rich lipoproteins, diagnostic criteria, cardiovascular risk, NHANES
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review